Throughout 2021, Myasthenia Gravis News has brought you coverage on the latest scientific advancements and clinical trials related to myasthenia gravis (MG). We look forward to continuing to be a resource to the MG community across 2022. Here are the top 10 most-read MG news stories of 2021, along with a…
Infants born to women with myasthenia gravis (MG) may develop a rare condition called transient neonatal myasthenia gravis (TNMG), which needs to be properly recognized in order to be appropriately managed, a new report highlights. “A neonate [newborn] born to a mother with MG is at risk for…
Merck KGaA has acquired Chord Therapeutics and the rights to continue developing CRD1 (cladribine), Chord’s lead candidate for treatment of generalized myasthenia gravis. “I am particularly pleased that Chord’s focus on severe, rare neurological conditions will be complemented by Merck’s established leadership with cladribine,” Arthur Roach, founder and…
The U.S. Food and Drug Administration (FDA) has accepted and placed on priority review an application seeking the approval of Ultomiris (ravulizumab-cwvz) to treat adults with generalized myasthenia gravis (gMG). The FDA set April through June as a target date range for its decision. Ultomiris is a monoclonal antibody…
Treatment with Ultomiris (ravulizumab-cwvz), a complement-blocking therapy, quickly eased symptom severity in adults with generalized myasthenia gravis (gMG), according to data from a Phase 3 trial. Findings were shared at the Myasthenia Gravis Foundation of America (MGFA) Scientific Sessions 2021 in the presentation, “Efficacy and safety…
Vyvgart (efgartigimod) has been approved by the U.S. Food and Drug Administration (FDA) to treat adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive, the therapy’s developer, Argenx, announced. According to Argenx, this patient group represents about 85% of all with generalized MG. “Today is…
In an older woman, myasthenia gravis (MG) onset followed surgery to remove a thymoma, or tumor of the thymus, a case study reported. Doctors should actively check for MG symptoms in patients with a thymoma before and after surgery, and measure the levels of self-reacting antibodies against acetylcholine receptors,…
Rozanolixizumab, UCB’s investigational antibody, may ease symptom severity in adults with generalized myasthenia gravis (MG), and help them carry on with daily activities, top-line data from the Phase 3 MycarinG study suggests. Moreover, rozanolixizumab, given as an under-the-skin (subcutaneous) infusion, was found to be generally safe and…
Determining whether two types of immune cells — T follicular helper cells and activated dendritic cells — are present or lacking in a thymoma, in addition to the levels of specific genes, may help to predict the risk of myasthenia gravis (MG) among people with these tumors, a small study suggests.
A type of myasthenia gravis (MG) caused by the presence of self-reactive antibodies targeting muscle-specific kinase (MuSK) affects mostly women and manifests with eye and bulbar symptoms (those involving the face and neck), according to a single-center study in Northwest China. In these cases, MG can be successfully managed…
Get regular updates to your inbox.